TrialGynecologic oncology2024

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.

Claire F Friedman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.